首页/数据集/Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

NIAID Data Ecosystem2026-05-01 收录

肿瘤治疗响应

实验肿瘤模型评估

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230269 数据链接链接失效反馈

官方服务：

资源简介：

WEHI-164 tumour samples taken after 75% debulking surgery, followed by treatment with poly(I:C) loaded hydrogel. Responders (complete regression) and non-responders (no delay in tumour growth)

应用场景：

创建时间：

2023-06-04

肿瘤治疗响应

基因功能缺失

We used CRISPR/Cas9 system to generate WT Control and RUNX1-KO MDS-L cells isolated as single clones from the parental MDS-L cell line. We have observed that RUNX1-KO MDS-L cells are resistant to Lena

NIAID Data Ecosystem100

Transcriptome analysis of Caspase-3 inhibited or not MDA-MB-231 tumors after docetaxel treatment

肿瘤治疗响应

血管生成机制

We report that the inhibition of Caspase-3 reduced angiogenesis in vivo after docetaxel treatment Overall design: Examination of the expression profile of Caspase-3 inhibited or not MDA-MB-231 tumors

NIAID Data Ecosystem80

We investigate the role of urea cycle dysregulation on cancer genome by perturbing the UC enzymes (over expression or knock-down) in different cancer cell lines.

尿素循环失调与癌症突变

肿瘤治疗响应

The urea cycle (UC) is the main pathway by which mammals dispose waste nitrogen. We find that specific alterations in the expression of most UC enzymes occurs in many tumors, leading to a general meta

NIAID Data Ecosystem60

Proteomic Characterization of the Gastric Cancer Response to Chemo- and Targeted therapies Reveals Axis of the Immune and Metabolic Pathways

胃癌蛋白质组学

肿瘤治疗响应

Herein, we set out to investigate the responses to first-line therapies (DOS, XELOX, and anti-HER2-based therapies) for GC through a comprehensive proteomic analysis. We constructed a GC cohort that c

Mendeley Data90

Multi-Omics Biomarkers of Response to Immunotherapy in Combination with Epigenetic Modulators

肿瘤治疗响应

生物标志物研究

Epigenetic immunomodulation by association of guadecitabine with ipilimumab (NIBIT-M4 Phase Ib trial, NCT02608437) has been shown to be safe and tolerable in advanced melanoma and to have significant

NIAID Data Ecosystem80

Responder vs non-responder in vivo tumours in response to poly(I:C) loaded hydrogel (WEHI-164)

资源简介：

相关数据集